We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Weapon Against Superbugs

By HospiMedica staff writers
Posted on 22 Jun 2005
A newly developed weapon against superbug methicillin-resistant Staphylococcus aureus (MRSA) is a permanent biocidal coating that is 99.8% effective in limiting the growth of MRSA.

Biacticap is being used as a coating for carbonless paper, where independent testing has found it to be effective in limiting the growth of MRSA. More...
Paper, used for doctors' notes and patient records, is an excellent host and carrier for all types of bacteria including MRSA, serving as a mechanism for cross-contamination between doctors and patients, patients and hospital employees, and between different hospital departments.

Biacticap was developed by Carrs Products (Birmingham, UK), a manufacturer of coated papers. The coating is also effective against other bacteria, including Listeria, Escherichia coli, and Salmonella. Carrs Products plans to extend the treatment to other flexible substrates such as plastics, film, nonwoven materials, and textiles, so that Biacticap would be able to protect most flexible surfaces in the hospital.

"Bacteria can quickly become resistant to antibiotics as a result of mutation, and therefore represent an ongoing healthcare threat,” said Tony Davis, sales and marketing director of Carrs Products. "In contrast, because Biacticap is inorganic, it provides continuous protection against bacteria mutations, which cannot become immune to its antimicrobial action.”


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.